- In February 2024, Takeda and Biological E announced a collaboration to produce 50 million dengue vaccines, enhancing efforts to combat the disease. In addition, Miltenyi Biotec unveiled the Hyderabad Center for Cell and Gene Therapy Services, focusing on advanced therapeutic solutions. The BioAsia 2024 event showcased significant breakthroughs in the pharmaceutical industry, highlighting innovations and advancements in healthcare
- In April 2023, health authorities in Argentina approved the use of a Japanese dengue vaccine, which requires administration in two doses spaced three months apart. This decision marks a significant step in enhancing dengue prevention efforts within the country. The two-dose regimen is designed to ensure optimal immunity against the disease
- In May 2023, Takeda announced that its dengue vaccine, QDENGA®, received multiple approvals, including one from Brazil's National Health Surveillance Agency in March 2023. This approval permits the vaccine's use in individuals aged 4 to 60 years, offering protection against all four dengue virus serotypes. Takeda's advancements in securing these approvals demonstrate its ongoing efforts to combat dengue fever effectively
- In March 2021, Takeda Pharmaceutical Company Limited announced that its dengue vaccine candidate, TAK-003, received approval from the European Medicines Agency (EMA) for use in preventing outbreaks among individuals aged 4 to 60. The company plans to seek regulatory approvals for this vaccine in several countries, including Argentina, Brazil, Colombia, Indonesia, Malaysia, Mexico, Singapore, Sri Lanka, and Thailand throughout 2021. This move reflects Takeda's commitment to expanding access to dengue prevention globally
Frequently Asked Questions
The market is segmented based on Segmentation, By Type (Live Attenuated Vaccine, Chimeric Live Attenuated Vaccine, Inactivated Vaccine, Subunit Vaccine, and Nucleic Acid Based Vaccine), Treatment (Diuretic, Anti-Allergic, Blood Thinners, and Others), Route of Administration (Oral, Parenteral, and Others), End-Users (Hospitals, Homecare, Specialty Clinics, and Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy) – Industry Trends and Forecast to 2031
.
The Global Dengue Vaccine Market size was valued at USD 592.01 USD Million in 2023.
The Global Dengue Vaccine Market is projected to grow at a CAGR of 11.7% during the forecast period of 2024 to 2031.
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America..
